Tumor suppressive function of E2F-1 on PTEN-induced serrated colorectal carcinogenesis.
Animals
Apoptosis
Carcinogenesis
Colorectal Neoplasms
/ enzymology
DNA Damage
E2F1 Transcription Factor
/ genetics
Gene Expression Regulation, Neoplastic
HT29 Cells
Humans
Mice, Knockout
Mitogen-Activated Protein Kinases
/ metabolism
PTEN Phosphohydrolase
/ genetics
Signal Transduction
Tumor Suppressor Proteins
/ genetics
ras Proteins
/ metabolism
E2F-1
PTEN
colorectal carcinoma
serrated pathway
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
08
03
2018
revised:
22
08
2018
accepted:
04
09
2018
pubmed:
13
9
2018
medline:
20
12
2019
entrez:
13
9
2018
Statut:
ppublish
Résumé
Many human cancers present Phosphatase and tensin homolog (PTEN) deficiency and between 20 and 30% of colorectal tumors show PTEN loss. The transcription factor, E2 promoter binding factor 1 (E2F-1), exhibits tumor promoter or suppressive functions depending on cellular type and tissue context, but its role in the progression and development of colorectal carcinogenesis was largely unknown. Here, using a tamoxifen-inducible PTEN knockout mouse model, we have demonstrated that loss of PTEN leads to the development of colorectal tumorigenesis through the serrated pathway. Next, we studied PTEN loss-driven colorectal lesions in the context of E2F-1 deficiency in vivo. Our results revealed that monoallelic and biallelic absence of E2F-1 led to an increased incidence and progression of serrated tumorigenesis induced by PTEN loss. Finally, we investigated the mechanisms by which double PTEN/E2F-1 deficiency leads to enhanced tumorigenesis. We found that colorectal tumors from PTEN/E2F-1 double knockout mice and the human colorectal carcinoma cell line HT29 with shRNA-mediated downregulation of PTEN and E2F-1 exhibit hyperactivation of the RAS-MAPK pathway, accumulation of DNA damage and resistance to apoptosis. To date, this is the first preclinical study evaluating the effect of genetic deletion of E2F-1 in colorectal malignancies driven by PTEN deficiency. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Substances chimiques
E2F1 Transcription Factor
0
E2F1 protein, human
0
E2f1 protein, mouse
0
Tumor Suppressor Proteins
0
Mitogen-Activated Protein Kinases
EC 2.7.11.24
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Pten protein, mouse
EC 3.1.3.67
ras Proteins
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
72-85Informations de copyright
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.